Skip to content
Screener

Beam Therapeutics BEAM Operating Lease Liabilities (Current)

Operating Lease Liabilities (Current) at other companies

Arrowhead Research logo
Arrowhead ResearchARWR
$7.77M+14.6%
MGN
MagniteMGNI
$23.86M+23.1%
Wave Life Sciences logo
Wave Life SciencesWVE
$3.51M-56.9%
Intellia Therapeutics logo
Intellia TherapeuticsNTLA
$23.34M-13.5%
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
$18.61M+6.3%
Prime Medicine logo
Prime MedicinePRME
$8.97M+23.6%

Other financials

Income statement

See full
Revenue$31.7M+325%
Operating income-$107.2M+10.1%
Net income-$94.3M+12.9%
EPS (diluted)-$0.91+26.0%

Balance sheet

See full
Cash & equivalents$288.3M-45.4%
Total debt$250.8M+58.6%
Total equity$1.2B+3.1%
Total assets$1.5B+0.9%

Cash flow

See full
Operating cash flow-$128.5M-23.7%
CapEx$2.2M-27.2%
Free cash flow-$130.7M-22.2%

Valuation

See full
Market cap$2.84B+63.5%
Enterprise value$2.8B+74.1%
P/S17.3×-11.5×

Profitability

See full
Operating margin-226.6%-90.5pp
Net margin-742.7%—
FCF margin-234%-86.6pp

Returns & leverage

See full
Return on equity-47.1%—
Debt / equity0.2×+0.1×
Current ratio17×+8.2×

Where this comes from

Reported directly by Beam Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityCurrent.

The source filing: Beam Therapeutics’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 7:22 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-210338
Line itemMarch 31,2026December 31,2025
Accrued expenses and other current liabilities39,29155,267
Current portion of derivative liabilities5,2007,700
Current portion of deferred revenue3046,659
Current portion of lease liability14,78114,364
Current portion of contingent consideration liabilities2,7032,714
Total current liabilities74,56596,935
Long-term lease liability135,848139,759
Long-term portion of contingent consideration liabilities5,4495,952

Item 1. Financial Statements (Unaudited)

FAQ

What is Beam Therapeutics's operating lease liabilities (current)?
Beam Therapeutics (BEAM) reported operating lease liabilities (current) of $14.78M in Q1 2026.
How has Beam Therapeutics's operating lease liabilities (current) changed year-over-year?
Beam Therapeutics's operating lease liabilities (current) increased by 11.9% year-over-year, from $13.21M to $14.78M.
What is the long-term trend for Beam Therapeutics's operating lease liabilities (current)?
Over 5 years (2020 to 2025), Beam Therapeutics's operating lease liabilities (current) has grown at a 27.8% compound annual growth rate (CAGR), from $4.22M to $14.36M.
What does operating lease liabilities (current) mean?
The current portion of operating lease obligations due within one year, representing committed future lease payments under ASC 842.

Ask your AI about Beam Therapeutics's operating lease liabilities (current).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude